We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+7.83%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$658M
AUM Growth
-$44.8M
(-6.4%)
Cap. Flow
-$69.2M
Cap. Flow
% of AUM
-10.5%
Top 10 Holdings %
Top 10 Hldgs %
35.22%
Holding
143
New
39
Increased
27
Reduced
22
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$10.3M |
| 2 |
STAAR Surgical
STAA
|
+$7.04M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$6.66M |
| 4 |
Zimmer Biomet
ZBH
|
+$6.03M |
| 5 |
Avantor
AVTR
|
+$4.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$10.4M |
| 2 |
Axogen
AXGN
|
+$6.9M |
| 3 |
CELG
Celgene Corp
CELG
|
+$4.72M |
| 4 |
Axsome Therapeutics
AXSM
|
+$4.13M |
| 5 |
Globus Medical
GMED
|
+$3.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.69% |
| 2 | Industrials | 1.24% |
| 3 | Consumer Staples | 0.68% |
| 4 | Materials | 0.13% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Coherus Oncology
CHRS
$185M
| $2.41M | 0.37% |
109,196
-56,417
| -34% | -$980K |
|
|
BEAT
77
PUT
DELISTED
BioTelemetry, Inc.
BEAT
| $2.41M | 0.37% |
+50,000
| New | +$2.63M |
|
78
Incyte
INCY
$24.6B
| $2.41M | 0.37% |
28,318
| – | – |
|
|
MSON
79
DELISTED
Misonix Inc
MSON
| $2.37M | 0.36% |
+93,045
| New | +$1.92M |
|
|
STML
80
DELISTED
Stemline Therapeutics, Inc.
STML
| $2.35M | 0.36% |
153,598
+115,514
| +303% | +$1.67M |
|
81
Glaukos
GKOS
$10.7B
| $2.26M | 0.34% |
+30,000
| New | +$2.15M |
|
82
LivaNova
LIVN
$4.25B
| $2.16M | 0.33% |
30,000
-10,000
| -25% | -$732K |
|
83
Artivion
AORT
$1.32B
| $2.1M | 0.32% |
+70,000
| New | +$2.08M |
|
|
QTNT
84
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $2.04M | 0.31% |
5,467
| – | – |
|
85
CALL
Novavax
NVAX
$1.28B
| $1.92M | 0.29% |
+327,800
| New | +$2.58M |
|
86
KALA BIO
KALA
$14.7M
| $1.91M | 0.29% |
120
| – | – |
|
87
Personalis
PSNL
$1.5B
| $1.76M | 0.27% |
+65,000
| New | +$1.84M |
|
88
Adaptive Biotechnologies
ADPT
$4.1B
| $1.69M | 0.26% |
+35,000
| New | +$1.55M |
|
89
Integra LifeSciences
IART
$1.35B
| $1.4M | 0.21% |
+25,000
| New | +$1.29M |
|
|
QTNT
90
CALL
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $1.05M | 0.16% |
2,813
| – | – |
|
|
AMRS
91
DELISTED
Amyris Inc.
AMRS
| $882K | 0.13% |
+247,668
| New | +$975K |
|
|
VRAY
92
CALL
DELISTED
ViewRay, Inc.
VRAY
| $881K | 0.13% |
100,000
-68,700
| -41% | -$558K |
|
93
Tandem Diabetes Care
TNDM
$1.63B
| $645K | 0.1% |
10,000
-30,000
| -75% | -$1.94M |
|
|
APTO
94
DELISTED
Aptose Biosciences, Inc.
APTO
| $392K | 0.06% |
+333
| New | +$306K |
|
|
GRCE
95
Grace Therapeutics
GRCE
$44.6M
| $380K | 0.06% |
6,940
+2,605
| +60% | +$114K |
|
96
VistaGen Therapeutics
VTGN
$11.2M
| $308K | 0.05% |
14,167
| – | – |
|
|
SYNH
97
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $255K | 0.04% |
+5,000
| New | +$233K |
|
|
98
Axsome Therapeutics
AXSM
$11.4B
| $201K | 0.03% |
7,800
-205,845
| -96% | -$4.13M |
|
99
PUT
ADMA Biologics
ADMA
$2.23B
| – | – |
-477,800
| Closed | -$1.81M |
|
100
PUT
Align Technology
ALGN
$12.3B
| – | – |
-25,000
| Closed | -$7.11M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q2 2019 Portfolio in Review
As of Q2 2019, Pura Vida Investments held 143 positions worth $658M, down 6.4% from $703M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $69.2M in Q2 2019, closing 45 positions and reducing 22 holdings. Its most notable exit was Dentsply Sirona, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 36% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Pura Vida Investments opened a new position in Smith & Nephew worth $10.9M.
- Pura Vida Investments's largest Q2 2019 buy was Smith & Nephew: 250,000 shares worth $10.9M.
- Pura Vida Investments added most to STAAR Surgical in Q2 2019, an estimated $7.04M increase.
- Pura Vida Investments's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $4.13M.
- Pura Vida Investments fully exited Dentsply Sirona in Q2 2019, selling an estimated $10.4M.
- Pura Vida Investments's ten largest holdings make up 35% of its $658M portfolio in Q2 2019.
- Pura Vida Investments opened 39 new positions and closed 45 in Q2 2019.
- Pura Vida Investments's portfolio value fell 6.4% quarter-over-quarter to $658M.
Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.